High-Throughput Multiplexed Peptide-Centric Profiling Illustrates Both Substrate Cleavage Redundancy and Specificity in the MMP Family.

Matrix metalloproteinases (MMPs) play incompletely understood roles in health and disease. Knowing the MMP cleavage preferences is essential for a better understanding of the MMP functions and design of selective inhibitors. To elucidate the cleavage preferences of MMPs, we employed a high-throughput multiplexed peptide-centric profiling technology involving the cleavage of 18,583 peptides by 18 proteinases from the main sub-groups of the MMP family. Our results enabled comparison of the MMP substrates on a global scale, leading to the most efficient and selective substrates. The data validated the accuracy of our cleavage prediction software. This software allows us and others to locate, with nearly 100% accuracy, the MMP cleavage sites in the peptide sequences. In addition to increasing our understanding of both the selectivity and the redundancy of the MMP family, our study generated a roadmap for the subsequent MMP structural-functional studies and efficient substrate and inhibitor design.

[1]  A. Strongin,et al.  Matrix-dependent Proteolysis of Surface Transglutaminase by Membrane-type Metalloproteinase Regulates Cancer Cell Adhesion and Locomotion* , 2001, The Journal of Biological Chemistry.

[2]  Christopher M. Overall,et al.  A Statistics-based Platform for Quantitative N-terminome Analysis and Identification of Protease Cleavage Products* , 2010, Molecular & Cellular Proteomics.

[3]  P. Daugherty,et al.  Directed evolution of protease beacons that enable sensitive detection of endogenous MT1-MMP activity in tumor cell lines. , 2011, Chemistry & biology.

[4]  Oliver Schilling,et al.  Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites , 2008, Nature Biotechnology.

[5]  High throughput substrate phage display for protease profiling. , 2009, Methods in molecular biology.

[6]  Christopher M Overall,et al.  Proteomics Discovery of Metalloproteinase Substrates in the Cellular Context by iTRAQ™ Labeling Reveals a Diverse MMP-2 Substrate Degradome*S , 2007, Molecular & Cellular Proteomics.

[7]  Alex Y Strongin,et al.  Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer. , 2010, Cancer research.

[8]  C. Overall,et al.  Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. , 2008, Blood.

[9]  F. Gomis-Rüth,et al.  Structural aspects of the metzincin clan of metalloendopeptidases , 2003, Molecular biotechnology.

[10]  Ying Zhang,et al.  Structural determinants of limited proteolysis. , 2011, Journal of proteome research.

[11]  C. Overall,et al.  Membrane protease degradomics: proteomic identification and quantification of cell surface protease substrates. , 2009, Methods in molecular biology.

[12]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[13]  Christopher M Overall,et al.  Identification of proteolytic products and natural protein N-termini by Terminal Amine Isotopic Labeling of Substrates (TAILS). , 2011, Methods in molecular biology.

[14]  A. Strongin,et al.  Quantitative FRET Imaging to Visualize the Invasiveness of Live Breast Cancer Cells , 2013, PloS one.

[15]  H. Mori,et al.  CD44 directs membrane‐type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin‐like domain , 2002, The EMBO journal.

[16]  Jeffrey W. Smith,et al.  Inflammatory Proprotein Convertase-Matrix Metalloproteinase Proteolytic Pathway in Antigen-presenting Cells as a Step to Autoimmune Multiple Sclerosis* , 2009, The Journal of Biological Chemistry.

[17]  C. Overall,et al.  Multiplex N-terminome Analysis of MMP-2 and MMP-9 Substrate Degradomes by iTRAQ-TAILS Quantitative Proteomics* , 2010, Molecular & Cellular Proteomics.

[18]  X. Puente,et al.  Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. , 2008, Cancer research.

[19]  C. Overall,et al.  Proteomic discovery of protease substrates. , 2007, Current opinion in chemical biology.

[20]  C. Overall,et al.  Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. , 2010, Biochimica et biophysica acta.

[21]  Piotr Cieplak,et al.  Matrix Metalloproteinase Proteolysis of the Myelin Basic Protein Isoforms Is a Source of Immunogenic Peptides in Autoimmune Multiple Sclerosis , 2009, PloS one.

[22]  A. Strongin,et al.  Microarray-based Transcriptional and Epigenetic Profiling of Matrix Metalloproteinases, Collagens, and Related Genes in Cancer* , 2010, The Journal of Biological Chemistry.

[23]  A. Strongin,et al.  Processing of Integrin αv Subunit by Membrane Type 1 Matrix Metalloproteinase Stimulates Migration of Breast Carcinoma Cells on Vitronectin and Enhances Tyrosine Phosphorylation of Focal Adhesion Kinase* , 2002, The Journal of Biological Chemistry.

[24]  H. Birkedal‐Hansen,et al.  MT1‐MMP: A tethered collagenase , 2004, Journal of cellular physiology.

[25]  U. auf dem Keller,et al.  Proteomic approaches to uncover MMP function. , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[26]  X. Puente,et al.  Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.

[27]  S. Itohara,et al.  Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice , 2004, Oncogene.

[28]  F. Gomis-Rüth.  Catalytic Domain Architecture of Metzincin Metalloproteases* , 2009, The Journal of Biological Chemistry.

[29]  K. Gevaert,et al.  Improved visualization of protein consensus sequences by iceLogo , 2009, Nature Methods.

[30]  B. Bauvois,et al.  New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. , 2012, Biochimica et biophysica acta.

[31]  R. Kizek,et al.  Matrix metalloproteinases. , 2010, Current medicinal chemistry.

[32]  A. Strongin,et al.  New Details of HCV NS3/4A Proteinase Functionality Revealed by a High-Throughput Cleavage Assay , 2012, PloS one.

[33]  L. Cantley,et al.  Determination of protease cleavage site motifs using mixture-based oriented peptide libraries , 2001, Nature Biotechnology.

[34]  A. Strongin,et al.  Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer , 2011, Biomolecular concepts.

[35]  C. Overall,et al.  Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding , 2008, Molecular and Cellular Biology.

[36]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[37]  Jeffrey W. Smith,et al.  A Unique Substrate Recognition Profile for Matrix Metalloproteinase-2* , 2002, The Journal of Biological Chemistry.

[38]  Christopher M Overall,et al.  Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. , 2008, Molecular & cellular proteomics : MCP.

[39]  A. Strongin,et al.  Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. , 2002, The Journal of biological chemistry.

[40]  Gillian Murphy,et al.  Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.

[41]  Georgina S. Butler,et al.  Identification of cellular MMP substrates using quantitative proteomics: isotope-coded affinity tags (ICAT) and isobaric tags for relative and absolute quantification (iTRAQ). , 2010, Methods in molecular biology.

[42]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[43]  Jeffrey W. Smith,et al.  Basis for substrate recognition and distinction by matrix metalloproteinases , 2014, Proceedings of the National Academy of Sciences.

[44]  P. Čapek,et al.  A Highly Scalable Peptide-Based Assay System for Proteomics , 2012, PloS one.

[45]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[46]  H. Nagase,et al.  Elucidating the Function of Non catalytic Domains of Collagenases and Aggrecanases , 2008, Connective tissue research.

[47]  S. Zucker,et al.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment , 2000, Oncogene.

[48]  Piotr Cieplak,et al.  CleavPredict: A Platform for Reasoning about Matrix Metalloproteinases Proteolytic Events , 2015, PloS one.

[49]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[50]  L. Kotra,et al.  Matrix metalloproteinases: structures, evolution, and diversification , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  Christopher M Overall,et al.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.

[52]  A. Strongin,et al.  Substrate Cleavage Profiling Suggests a Distinct Function of Bacteroides fragilis Metalloproteinases (Fragilysin and Metalloproteinase II) at the Microbiome-Inflammation-Cancer Interface* , 2013, The Journal of Biological Chemistry.

[53]  H. Mori,et al.  Membrane-Type 1 Matrix Metalloproteinase Cleaves Cd44 and Promotes Cell Migration , 2001, The Journal of cell biology.

[54]  C. Overall,et al.  Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry. , 2007, Current pharmaceutical design.

[55]  K. Maskos.  Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. , 2005, Biochimie.

[56]  Yunbo Shi,et al.  Genome-wide identification of Xenopus matrix metalloproteinases: conservation and unique duplications in amphibians , 2009, BMC Genomics.

[57]  A. Dufour,et al.  Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. , 2013, Trends in pharmacological sciences.

[58]  A. Strongin,et al.  Structural and functional diversity of metalloproteinases encoded by the Bacteroides fragilis pathogenicity island , 2014, The FEBS journal.

[59]  A. Strongin,et al.  High-Resolution Analysis and Functional Mapping of Cleavage Sites and Substrate Proteins of Furin in the Human Proteome , 2013, PloS one.

[60]  B. Fingleton,et al.  Moving targets: Emerging roles for MMPs in cancer progression and metastasis. , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[61]  Piotr Cieplak,et al.  Sequence‐derived structural features driving proteolytic processing , 2014, Proteomics.